Rules of Transfusion
Rules of Transfusion
Rules of Transfusion
Your patients life may depend on your ability to prevent, detect, and manage a transfusion reaction.
By Sabrina Bielefeldt, BSN, RN, OCN, and Justine DeWitt, BSN, RN, OCN
BLOOD TRANSFUSIONS are a lifesustaining and life-saving treatmentbut they arent without risk. Conditions that warrant blood transfusions range from acute trauma to intraoperative blood loss to compromised blood-cell production secondary to disease or treatment. If youre a nurse on the front line of patient care, you must be adept at administering blood products safely and managing adverse reactions with speed and confidence.
lution, oxygen, suction, and a hypersensitivity kit. Be sure youre familiar with the specific product to be transfused, the appropriate administration rate, and required patient monitoring. Be aware that the type of blood product and patients condition usually dictate the infusion rate. For example, blood must be infused faster in a trauma victim whos rapidly losing blood than in a 75-year-old patient with heart failure, who may not be able to tolerate rapid infusion. Know what personnel will be available in the event of a reaction, and how to contact them. Resources should include the on-call physician and a blood bank representative. Before hanging the blood product, thoroughly double-check the patients identification and verify the actual product. Check the unit to be transfused against patient identifiers, per facility policy. Infuse the blood product with normal saline solution only, using filtered tubing.
Premedication To help prevent immunologic transfusion reactions, the physician may order such medications as acetaminophen and diphenhydramine before
American Nurse Today 27
February 2009
Type of reaction
Acute hemolytic reaction Life-threatening complement-mediated immune reaction causing simultaneous intravascular coagulation and hemolysis, DIC, renal failure, and shock Onset: within minutes to 24 hours of transfusion Delayed hemolytic reaction Noncomplement-mediated immune reaction causing gradual extravascular hemolysis when recipient antibodies bind to and coat donor RBCs Onset: days to weeks after transfusion Febrile nonhemolytic reaction Most common type of transfusion reaction May be immune or complement mediated Recipient antibodies react with donor WBC antigens or fragments Doesnt cause hemolysis May result from cytokine accumulation during blood storage Onset: within minutes to hours of transfusion Mild allergic reaction Occurs when transfused allergens in plasma activate recipients IgE antibodies Marked by release of histamine by recipients mast cells and basophils Onset: immediately or within 24 hours of transfusion Anaphylactic reaction May occur in patients with IgA deficiency who have anti-IgA antibodies, causing severe to life-threatening immune response Onset: immediately or within 24 hours after transfusion Transfusion-related acute lung injury Occurs when donor WBC antibodies react to recipients circulating WBCs Life-threatening complement-mediated reaction causing surge of neutrophils into lungs, resulting in pulmonary damage, pulmonary edema, and respiratory distress Onset: immediately or within 24 hours after transfusion
Nursing interventions
Stop transfusion immediately. Hydrate with normal saline solution, as ordered. Check vital signs frequently. Support airway, blood pressure, heart rate, and urine output. Be aware that patient usually requires ICU management. Patient may not need treatment. If ordered, replace lost blood cells with additional transfusion.
Prevention
Follow facility policies and procedures for obtaining pretransfusion blood bank specimens. Adhere carefully to patient identification procedures.
Mild fever Jaundice Decreased posttransfusion hematocrit Elevated lactate dehydrogenase and serum bilirubin levels Fever (temperature increase of at least 1 C [1.8 F] above baseline) Chills Flushing Nausea Headache Vague discomfort
Follow all facility policies and procedures for obtaining pretransfusion blood bank specimens. Adhere carefully to patient identification verification procedures. Premedicate with antipyretic and antihistamine, as ordered. Give leukocyte-reduced and/or irradiated products, as ordered. Screen for HLA antibodies in patients with repeated febrile reactions.
Stop transfusion immediately. Help rule out other causes of fever. Manage symptoms as appropriate.
Stop transfusion immediately. Give antihistamines, steroids, or both, as ordered. If ordered, resume transfusion when symptoms subside.
Lack of fever Hypotension Stridor Bronchospasm Dyspnea Cramps Flushing Chest tightness Decreased oxygen saturation
Stop transfusion immediately. Keep vein open with normal saline solution. Obtain vital signs frequently. Support airway, blood pressure, and heart rate. If ordered, give steroids and epinephrine. Stop transfusion immediately. Keep vein open with normal saline solution. Obtain vital signs frequently. Support airway, blood pressure, heart rate, and urine output. Provide supportive care for respiratory symptoms. Know that patient may require intubation.
If ordered, ensure special preparation of blood products, such as washed cells and products from IgA-deficient donors.
Sudden onset of respiratory distress during or shortly after transfusion Acute noncardiogenic pulmonary edema, pulmonary infiltrates with hypoxia
Ensure donor screening for HLA and granulocyte antibodies when possible. Administer washed RBCs, as ordered, to eliminate plasma from identified donors.
28
Volume 4, Number 2
Nursing interventions
Stop transfusion immediately. Position patient upright. Provide supplemental oxygen, as ordered. Check vital signs frequently. Support airway, blood pressure, and heart rate. Give diuretics (such as furosemide), if ordered, to reduce intravascular plasma volume.
Prevention
Infuse at suggested rate of 2 to 2.5 mL/kg/hour, if ordered. For high-risk patients, recommended rate is 1 mL/kg/hour.
Fever or hypothermia Chills or rigors Abdominal pain Back pain Nausea, vomiting Hypotension Oliguria
Stop transfusion immediately. Keep vein open with normal saline solution. If ordered, give empiric broadspectrum antibiotics (usually a combination of vancomycin and aminoglycoside). Notify blood bank and microbiology lab of reaction. Draw cultures as appropriate and send them for microbiologic testing. Provide supportive care for acute bleeding, if necessary. Teach patient about bleeding precautions. As ordered, administer corticosteroids and IVIG.
Ensure extensive donor screening, leukocyte reduction, and proper storage and handling of transfusion product. Carefully inspect product for abnormalities before starting transfusion. Infuse blood product for maximum of 4 hours (6 for fresh frozen plasma).
Chills or fever Wet purpura (mucous membrane hemorrhage) Epistaxis GI or urinary tract bleeding Intracranial hemorrhage Bronchospasm
Fever Cutaneous eruption that spreads distally Erythroderma and bullae Nausea, vomiting Profuse watery diarrhea Abnormal liver function tests Anorexia
Know that condition resists most immunosuppressive therapies, including glucocorticoids, antithymocyte globulin, cyclosporine, cyclophosphamide, and T-cell monoclonal antibodies.
Provide symptomatic care as indicated. Prevention is crucial due to lack of effective therapy. Ensure irradiation and leukocyte reduction of blood product.
Abbreviation key: DIC: disseminated intravascular coagulation; HLA: human leukocyte antigen; IgA: immunoglobulin A; IgE: immunoglobulin E; IVIG: I.V. immune globulin; RBCs: red blood cells; WBCs: white blood cells
the transfusion begins to prevent fever and histamine release. Febrile nonhemolytic transfusion reactions seem to be linked to blood components, such as platelets or fresh frozen plasma, as opposed to packed red blood cells; thus, premedication may be indicated for patients who will receive these products. Such reactions may be mediated by donor
leukocytes in the plasma, causing allosensitization to human leukocyte antigens. Cytokine generation and accumulation during blood component storage may play a contributing role. Leukocyte-reduced and irradiated blood products Use of blood products that have been leukocyte-reduced, irradiated,
or both has been shown to reduce complications stemming from an immunologic response. In organ transplant candidates, these products reduce the risk of graft rejection.
February 2009
Actions
Improves tissue oxygenation, expands volume, and promotes coagulation
Nursing considerations
Rarely used today except for patients needing rapid, massive replacement of lost blood (more than 25% of blood volume) Requires ABO and Rh crossmatching Composed of 70% to 80% hematocrit; one of the most viscous blood products to transfuse Require ABO and Rh crossmatching
Increase bloods oxygen-carrying capacity in anemic patients; replace blood lost during surgery
Platelets Contain concentrate made from whole blood (random donor) or plasmapheresis (single donor); also may contain plasma and some RBCs and WBCs Fresh frozen plasma Contains normal components of blood plasma, including fibrinogen, frozen within 8 hours of removal from whole blood
Aid coagulation by controlling or preventing bleeding linked to deficient platelet number or function
Avoid filters used to transfuse whole blood or PRBCs, as red cell debris accumulated in filter may trap platelets; use new filter instead. Doesnt require ABO crossmatching. Rh antibody status is relevant for infants and small children. Less viscous than whole blood or PRBCs; therefore, blood-component recipient set may be used. Monitor coagulation studies. Requires ABO crossmatching, but Rh antibody status is irrelevant
Aids coagulation in actively bleeding patients with clotting deficiencies and in patients who will undergo invasive procedures likely to cause bleeding
when the product arrives from the blood bank to when the infusion must be completed. (See Quick guide to blood products.) Failing to adhere to these time guidelines increases the risk of such complications as bacterial contamination. Detecting and managing transfusion reactions During the transfusion, stay alert for signs and symptoms of a reaction, such as fever or chills, flank pain, vital sign changes, nausea, headache, urticaria, dyspnea, and bronchospasm. Optimal management of reactions begins with a standardized protocol for monitoring and documenting vital signs. As dictated by facility policy, obtain the patients vital signs before, during, and after the transfusion. If you suspect a transfusion reaction, take these immediate actions:
30 American Nurse Today
Stop the transfusion. Keep the I.V. line open with normal saline solution. Notify the physician and blood bank. Intervene for signs and symptoms as appropriate. Monitor the patients vital signs. Also return the blood product to the blood bank and collect laboratory samples according to facility policy. If and when clinically necessary, resume the transfusion after obtaining a physician order. Carefully document transfusion-related events according to facility policy; be sure to include the patients vital signs, other assessment findings, and nursing interventions. Most fatal transfusion reactions result from human error. The most important step in preventing such error is to know and follow your facilitys policies and procedures for
administering blood products. Be aware, though, that prevention isnt always possiblewhich means you must be able to anticipate potential reactions and be prepared to manage them effectively. To promote good patient outcomes, you must be knowledgeable about the best practices described in this article. * Selected references
Silvergleid A. Immunologic blood transfusion reactions. UpToDate. October 17, 2008. www.uptodate.com/patients/content/topic .do?topicKey=~EE8E1UGcUSyKQT. Accessed December 22, 2008. Visit www.AmericanNurseToday.com/journal for a complete list of selected references.
Sabrina Bielefeldt and Justine DeWitt are Oncology Certified Nurses at Georgetown University Hospital in Washington, D.C. Ms. Bielefeldt is the Clinical Manager and Ms. DeWitt is a Clinical Nurse IV on the Inpatient Hematology Oncology unit. Ms. DeWitt also serves as Co-Chair of the hospitals Nursing Practice Council.
Volume 4, Number 2